OrbusNeich Medical Group Holdings Limited
業聚醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6929)

CHANGE OF OFFICERS AND COMPANY SECRETARY

The board (the "**Board**") of directors (the "**Directors**") of OrbusNeich Medical Group Holdings Limited (the "**Company**" and together with its subsidiaries, the "**Group**") announces the following changes to the Group's officers with effect from August 17, 2026.

APPOINTMENT OF CO-CHIEF EXECUTIVE OFFICER

The Board is pleased to announce that Ms. Kwai Ching Denise Lau ("**Ms. Lau**"), an Executive Director, (i) has been appointed as the Co-Chief Executive Officer of the Company, alongside Mr. David Chien ("**Mr. Chien**"); and (ii) has ceased to act as the Chief Operating Officer of the Company, with effect from August 17 2026.

The biographical details of Ms. Lau are set out as follows:

Ms. Lau, aged 52, has been a Director since July 22, 2021 and was redesignated as an Executive Director on September 29, 2021. She has been the Chief Operating Officer of the Group since September 14, 2020, and is primarily responsible for leading, overseeing and supervising the operation of the Group. Ms. Lau also holds directorships in the subsidiaries of the Group. Ms. Lau has more than 27 years of legal, business operation and management experience. She was trained and admitted as a solicitor in Hong Kong in 1999, and was subsequently admitted to practice law in England and Wales and the State of New York in 2000 and 2001, respectively. She worked as an attorney at Paul, Weiss, Rifkind, Wharton & Garrison from 2000 to 2006 and joined Morgan Stanley in February 2006, and left as managing director in April 2015. She joined the Group as the general counsel and senior vice president on April 3, 2018. Ms. Lau obtained her Bachelor of Laws degree from The University of Hong Kong in 1996 and obtained her

Postgraduate Certificate in Laws from the same university in 1997. She also obtained her master's degree in international economic law from the University of Warwick in the United Kingdom in January 2001. Ms. Lau has been the vice president of the Hangzhou Fuyang Association of Enterprises with Foreign Investment (杭州市富陽區外商投資企業協會) since April 2023, the founding member of Hong Kong Red Cross "EmpowerHer Network" since March 2025, the vice president of 7th Executive Committee of the Golden Bauhinia Women Entrepreneurs Association since May 2025 and a director of the board of director of the Yan Chai Hospital for its 59th Term since April 2026.

Ms. Lau has entered into a service contract with the Company, pursuant to which the terms of her directorship are subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the articles of association of the Company (the "**Articles of Association**") and the applicable Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). With effect from August 17, 2026, the annual basic salary payable to Ms. Lau for all positions she holds within the Group is HK$4,636,320. Ms. Lau is also entitled to receive discretionary bonuses and the employer's contributions to a retirement benefit scheme. The discretionary bonuses will be determined annually by the Board's Remuneration Committee with reference to her responsibilities within the Group, qualifications, experience and prevailing market remuneration levels.

Ms. Lau is the spouse of Mr. Chien, the Chairman, Executive Director and Co-Chief Executive Officer of the Group.

As at the date of this announcement, Mr. Chien and Ms. Lau held 55% and 45% of shareholdings of Harmony Tree Limited ("**HART**"), respectively. As such, under the Securities and Futures Ordinance (the "**SFO**"), Ms. Lau is deemed to be interested in 521,523,844 shares of the Company (the "**Shares**") held by HART.

Save as disclosed above, as at the date of this announcement, in relation to the above appointment, unless otherwise disclosed above: (1) Ms. Lau does not have any relationship with other Directors, senior management or substantial shareholder or controlling shareholder of the Company; (2) Ms. Lau is not interested in the Shares and underlying Shares within the meanings of Part XV of the SFO; (3) Ms. Lau did not hold any other directorships in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas, or hold other major appointments and professional qualifications; (4) there is no information to be disclosed pursuant to any of the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules; and (5) there is no other matter which needs to be brought to the attention of the shareholders of the Company pursuant to Rule 13.51(2) of the Listing Rules.

APPOINTMENT OF CHIEF OPERATING OFFICER

The Board is pleased to announce that Mr. Wing Shing Chen ("**Mr. Chen**"), an Executive Director, (i) has been appointed as the Chief Operating Officer of the Company; and (ii) has ceased to act as the Chief Financial Officer and Company Secretary of the Company, with effect from August 17, 2026.

The biographical details of Mr. Chen are set out as follows:

Mr. Chen, aged 45, has been the Director of the Company since July 22, 2021 and was redesignated as an Executive Director on September 29, 2021. Mr. Chen has been the Company Secretary of the Company since September 29, 2021, and the Chief Financial Officer of the Group since January 8, 2018. Mr. Chen also holds directorships in the subsidiaries of the Group. Mr. Chen has around 23 years of experience in auditing, accounting and corporate finance. He joined PricewaterhouseCoopers in December 2003 in the assurance practice and left as senior manager in February 2017. Before joining the Group, Mr. Chen worked in corporate finance in property development and investment sector in the Mainland of China. Mr. Chen joined the Group in April 2017 as the financial controller, and was later promoted as the Chief Financial Officer of the Group in January 2018. Mr. Chen obtained his Bachelor's degree in business administration, concentrating in financial engineering from The Chinese University of Hong Kong with first class honors in December 2003. He is a fellow certified public accountant in Hong Kong, the State of Washington and the State of Delaware of the United States. He is also a charter holder of the Chartered Financial Analyst Institute.

Mr. Chen has entered into a service contract with the Company, pursuant to which his terms of directorship are subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the Articles of Association and the applicable Listing Rules. With effect from August 17, 2026, the annual basic salary payable to Mr. Chen for all positions he holds within the Group is HK$3,554,640. Mr. Chen is also entitled to receive discretionary bonuses and the employer's contributions to a retirement benefit scheme. The discretionary bonuses will be determined annually by the Board's Remuneration Committee with reference to his responsibilities within the Group, qualifications, experience and prevailing market remuneration levels.

As at the date of this announcement, Mr. Chen is interested in (i) 6,138,409 Shares; and (ii) 400,000 underlying Shares by virtue of a pre-IPO share option scheme of the Company.

Save as disclosed above, as at the date of this announcement, in relation to the above appointment, unless otherwise disclosed above: (1) Mr. Chen does not have any relationship with other Directors, senior management or substantial shareholder or controlling shareholder of the Company; (2) Mr. Chen is not interested in the Shares and underlying Shares within the meanings of Part XV of the SFO; (3) Mr. Chen did not hold any other directorships in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas, or hold other major appointments and professional qualifications; (4) there is no information to be disclosed pursuant to any of the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules; and (5) there is no other matter which needs to be brought to the attention of the shareholders of the Company pursuant to Rule 13.51(2) of the Listing Rules.

APPOINTMENT OF CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY

The Board is pleased to announce that Ms. Man Ying Chan ("**Ms. Chan**") has been appointed as the Chief Financial Officer and Company Secretary of the Company with effect from August 17, 2026.

The biographical details of Ms. Chan are set out as follows:

Ms. Chan, aged 51, has been appointed as the Chief Financial Officer and Company Secretary of the Company since August 17, 2026 and is primarily responsible for overseeing the Group's financial, company secretarial and investor relations functions. She has over 28 years of experience in finance, accounting, auditing and corporate management. Prior to joining the Group, Ms. Chan served as the chief financial officer and company secretary for companies listed in Hong Kong. She also gained professional accounting and auditing experience with Deloitte Touche Tohmatsu. Ms. Chan holds a Bachelor of Business Administration degree in accounting from the Hong Kong University of Science and Technology. She is a fellow member of the Association of Chartered Certified Accountants and Hong Kong Institute of Certified Public Accountants.

The Board would like to take this opportunity to thank Ms. Lau and Mr. Chen for their continuous leadership in the Group, and to welcome Ms. Chan for joining the Company.

By order of the Board
OrbusNeich Medical Group Holdings Limited
Mr. David CHIEN
Chairman, Executive Director and Co-Chief Executive Officer

Hong Kong, August 17, 2026

As of the date of this announcement, the Board comprises Mr. David CHIEN, Ms. Kwai Ching Denise LAU and Mr. Wing Shing CHEN as Executive Directors; Mr. Ting San Peter Lionel LEUNG as Non-executive Director; and Mr. Yip Keung CHAN, Mr. Ka Keung LAU BBS, MH, JP and Dr. Lai Fan Gloria TAM as Independent Non-executive Directors.